医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s to Release Q2 and Half Year FY14 Results on October 31, 2013

2013年10月19日 PM10:55
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half Year ended September 30, 2013 on Thursday, October 31, 2013 after the Board Meeting. The results will be available on the Company’s website www.drreddys.com

Summary of Events

         
Event   Date and Time (IST)   Medium
Release of financial results   October 31st, after the Board Meeting  

Email, Media, Company website, Business Wire

Earnings Call   October 31st, 6.30 PM IST / 9:00 AM EDT   Hosted by the Company

(Details below)

Webcast of Earnings Call   October 31st, 6.30 PM IST / 9.00 AM EDT through November 5th, 2013  

URL available on Company’s website, www.drreddys.com

Transcripts of the Earnings call   Will be available on the Company’s website  

URL available on Company’s website, www.drreddys.com

   

Earnings Call

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance.

 
Conference Dial-In Numbers
Primary Number:   +91 22 6629 0356
Secondary Number:   +91 22 3065 0136
The numbers listed above are universally accessible from all networks and all countries.
Local Access Number:  

6000 1221
Available in – Ahmedabad, Bangalore, Bhubaneswar, Chandigarh, Chennai, Coimbatore, Delhi, Goa, Guntur, Gurgaon, Hyderabad, Indore, Jamshedpur, Kanpur, Kochi/Cochin, Kolhapur, Kolkata, Nagpur, Noida, Patna, Pune, Raipur, Rajkot, Surat, Trivandrum, Vadodara, Vijayawada
Accessible from all major carriers except BSNL/MTNL.
3940 3977
Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune
Accessible from all carriers.

International Toll Free Number:  

USA: 1 866 746 2133
UK: 0 808 101 1573
Singapore: 800 101 2045
Hong Kong: 800 964 448

 

No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early registration is encouraged. The operator will provide instructions on asking questions before and during the call.

Audio Webcast

The audio webcast of the earnings call will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through October 5th, 2013. For play back dial in phone No: 022 3065 1212 and ID: 375#.

Transcript

The transcript of the earnings call will also be available on the Company’s website.

About Dr. Reddy’s

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within Emerging Markets.

For more information, log on to: www.drreddys.com

*EDT- Eastern Daylight Saving Time

CONTACT

Dr. Reddy’s Laboratories
Investor Relations
Kedar
Upadhye, +91 40 66834297
kedaru@drreddys.com
or
Saunak
Savla, +91 40 49002135
saunaks@drreddys.com
or
Milan
Kalawadia (USA), +1 9082034931
mkalawadia@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PHCホールディングス株式会社:薬剤師の業務効率化を目指した保険薬局用電子薬歴システム「PharnesV-MX」を販売開始
  • LG化学举办“全球创新大赛 (GIC)”“寻找改变世界的创新技术”
  • HealthTap Powers Quality HealthCare to Multiple Asia eCommerce Awards
  • Mark Comerford Elected Chairman of Global Advanced Metals
  • オクタファルマ、Nuwiq®製剤の新しい有効成分含量が欧州で承認され、血友病A患者に対する投与法の柔軟性が高まると発表